867165-15-9 Usage
General Description
8-chloro-3-cyclobutyl-1-iodoimidazo[1,5-a]pyrazine is a chemical compound with the molecular formula C10H10ClIN4. It is a heterocyclic compound that contains both chlorine and iodine atoms, as well as a cyclobutyl group. 8-chloro-3-cyclobutyl-1-iodoimidazo[1,5-a]pyrazine has potential applications in the pharmaceutical industry, as it can be used as a building block in the synthesis of new organic molecules for drug discovery and development. Its unique structure and properties make it an interesting target for medicinal chemistry research, with potential use in the treatment of various diseases and conditions. Additionally, it may also have applications in other fields such as materials science and organic synthesis. More research and exploration of its potential uses are needed to fully understand its properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 867165-15-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,7,1,6 and 5 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 867165-15:
(8*8)+(7*6)+(6*7)+(5*1)+(4*6)+(3*5)+(2*1)+(1*5)=199
199 % 10 = 9
So 867165-15-9 is a valid CAS Registry Number.
867165-15-9Relevant articles and documents
SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES
-
Page/Page column 26, (2009/12/05)
Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.
UNSATURATED mTOR INHIBITORS
-
Page/Page column 43, (2010/11/28)
Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS
-
Page/Page column 431-432, (2008/06/13)
Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein XI, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
